NCT06449001View on ClinicalTrials.gov

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

PHASE3RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

May 28, 2027

Study Completion Date

March 10, 2028

Conditions
Paroxysmal Nocturnal HemoglobinuriaPNHExtravascular Hemolysis
Interventions
DRUG

Danicopan

Participants will receive danicopan on a weight-based dosing regimen.

Trial Locations (4)

77019

RECRUITING

Research Site, Paris

S7N 0W8

NOT_YET_RECRUITING

Research Site, Saskatoon

LS9 7TF

NOT_YET_RECRUITING

Research Site, Leeds

SE5 9RS

NOT_YET_RECRUITING

Research Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY